Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

10.1093/annonc/mdy245

Saved in:
Bibliographic Details
Main Authors: Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH Ingles, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, de Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, de Bono, JS, Banerji, U
Other Authors: MEDICINE
Published: OXFORD UNIV PRESS 2021
Subjects:
phase 1
m-TORC1/m-TORC2 inhibitor
combination therapy
ovarian cancer
squamous non-small-cell lung cancer
Online Access:https://scholarbank.nus.edu.sg/handle/10635/206997
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Similar Items

Similar Items